Fred Grossman
President at COYA THERAPEUTICS, INC.
Net worth: - $ as of 2024-03-30
Profile
Fred Grossman is currently the Director at Reunion Neuroscience, Inc. and the President & Chief Medical Officer at Coya Therapeutics, Inc. He previously worked as the Global Head-Medical Affairs Organization at Bristol Myers Squibb Co. from 2004 to 2010 and as the Head-Clinical Development & Medical Affairs at Sumitomo Pharma America, Inc. from 2010 to 2015.
He also served as the Chief Medical Officer at Mesoblast, Inc. and Co-President & Chief Medical Officer at Glenmark Pharmaceuticals Ltd.
In addition, he was the President & Chief Medical Officer at Glenmark Pharmaceuticals Inc., USA from 2015 to 2018 and the Chief Medical Officer at Mesoblast Ltd.
from 2019 to 2022.
Dr. Grossman received his undergraduate degree from Hahnemann University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
COYA THERAPEUTICS, INC.
-.--% | 2024-03-21 | 0 ( -.--% ) | - $ | 2024-03-30 |
Fred Grossman active positions
| Companies | Position | Start |
|---|---|---|
| COYA THERAPEUTICS, INC. | President | 2023-07-16 |
Reunion Neuroscience, Inc.
 Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | Director/Board Member | 2023-04-02 |
Former positions of Fred Grossman
| Companies | Position | End |
|---|---|---|
| MESOBLAST LIMITED | Chief Tech/Sci/R&D Officer | 2022-02-01 |
Glenmark Pharmaceuticals Inc., USA
 Glenmark Pharmaceuticals Inc., USA Pharmaceuticals: MajorHealth Technology Glenmark Pharmaceuticals USA, Inc. manufactures, markets, and distributes generic pharmaceutical products. It offers campral delayed-release tablets, differin gel, aclovate cream, aclovate topical ointment, ortho novum, and other related products. The company was founded in 2003 and is headquartered in Mahwah, NJ. | President | 2018-07-31 |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Corporate Officer/Principal | 2015-09-30 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 2010-09-30 |
Mesoblast, Inc.
 Mesoblast, Inc. Pharmaceuticals: MajorHealth Technology Mesoblast, Inc. manufactures and distributes biopharmaceutical products. It develops cellular medicines for under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The company was founded by Michael Schuster and Silviu Itescu in 2004 and is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | - |
Training of Fred Grossman
| Hahnemann University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GLENMARK PHARMACEUTICALS LIMITED | Health Technology |
| MESOBLAST LIMITED | Health Technology |
| COYA THERAPEUTICS, INC. | Health Technology |
 | Health Technology |
| Private companies | 3 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Mesoblast, Inc.
Mesoblast, Inc. Pharmaceuticals: MajorHealth Technology Mesoblast, Inc. manufactures and distributes biopharmaceutical products. It develops cellular medicines for under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The company was founded by Michael Schuster and Silviu Itescu in 2004 and is headquartered in New York, NY. | Health Technology |
Glenmark Pharmaceuticals Inc., USA
Glenmark Pharmaceuticals Inc., USA Pharmaceuticals: MajorHealth Technology Glenmark Pharmaceuticals USA, Inc. manufactures, markets, and distributes generic pharmaceutical products. It offers campral delayed-release tablets, differin gel, aclovate cream, aclovate topical ointment, ortho novum, and other related products. The company was founded in 2003 and is headquartered in Mahwah, NJ. | Health Technology |
- Stock Market
- Insiders
- Fred Grossman
